Precision Therapy Clinical Trial
Official title:
Cancer Hospital, Chinese Academy of Medical Sciences/National Cancer Center of China
Patients with salivary gland carcinoma were divided into groups according to HER2, NTRK, AR, TROP-2, etc. Patients in different groups were given precision targeted therapy or chemotherapy to evaluate the efficacy (ORR rate, etc.) and safety of precision neoadjuvant or conversion therapy.
1. Patients with locally advanced/recurrent or oligometastatic salivary gland carcinoma were divided into groups according to HER2, NTRK, AR, TROP-2, etc. Patients in different groups were given precision targeted therapy or chemotherapy to evaluate the efficacy (ORR rate, etc.) and safety of precision neoadjuvant or conversion therapy. 2. Patients with locally advanced/recurrent or metastatic salivary gland carcinoma with symptoms and rapid progression who could not tolerate or refuse surgery were divided into groups according to HER2, NTRK, AR, TROP-2, etc. Patients in different groups were given precise targeted therapy or chemotherapy to evaluate the efficacy (ORR rate, etc.) and safety of rescue therapy. 3. To explore biomarkers related to the efficacy of precision treatment of salivary gland cancer. ;